Applications and Advancements of CRISPR-Cas in the Treatment of Lung Cancer

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2024 Jan 8

PMID 38188023

Authors

Pan Lei

Yixin Ju

Fenfen Peng

Jie Luo

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the most malignant diseases and a major contributor to cancer-related deaths worldwide due to the deficiency of early diagnosis and effective therapy that are of great importance for patient prognosis and quality of life. Over the past decade, the advent of clustered regularly interspaced short palindromic repeats/CRISPR associated protein (CRISPR/Cas) system has significantly propelled the progress of both fundamental research and clinical trials of lung cancer. In this review, we review the current applications of the CRISPR/Cas system in diagnosis, target identification, and treatment resistance of lung cancer. Furthermore, we summarize the development of lung cancer animal models and delivery methods based on CRISPR system, providing novel insights into clinical diagnosis and treatment strategies of lung cancer.

References

Hussmann D, Madsen A, Jakobsen K, Luo Y, Sorensen B, Nielsen A . IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells. Oncotarget. 2017; 8(20):33300-33315. PMC: 5464869. DOI: 10.18632/oncotarget.16350. View

Cheng Q, Wei T, Farbiak L, Johnson L, Dilliard S, Siegwart D . Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. Nat Nanotechnol. 2020; 15(4):313-320. PMC: 7735425. DOI: 10.1038/s41565-020-0669-6. View

Thege F, Rupani D, Barathi B, Manning S, Maitra A, Rhim A . A Programmable In Vivo CRISPR Activation Model Elucidates the Oncogenic and Immunosuppressive Functions of MYC in Lung Adenocarcinoma. Cancer Res. 2022; 82(15):2761-2776. PMC: 9357118. DOI: 10.1158/0008-5472.CAN-21-4009. View

Gannon H, Kaplan N, Tsherniak A, Vazquez F, Weir B, Hahn W . Identification of an "Exceptional Responder" Cell Line to MEK1 Inhibition: Clinical Implications for MEK-Targeted Therapy. Mol Cancer Res. 2015; 14(2):207-15. PMC: 4755909. DOI: 10.1158/1541-7786.MCR-15-0321. View

Tang K, Constanzo J, Venkateswaran N, Melegari M, Ilcheva M, Morales J . Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. Clin Cancer Res. 2016; 22(23):5851-5863. PMC: 5122471. DOI: 10.1158/1078-0432.CCR-15-2603. View

Petroni G, Buque A, Coussens L, Galluzzi L . Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. Nat Rev Drug Discov. 2022; 21(6):440-462. DOI: 10.1038/s41573-022-00415-5. View

Westover D, Zugazagoitia J, Cho B, Lovly C, Paz-Ares L . Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol. 2018; 29(suppl_1):i10-i19. PMC: 6454547. DOI: 10.1093/annonc/mdx703. View

Kim S, Shin S, Kim E, Kim S, Park K, Oh S . Simple in Vivo Gene Editing via Direct Self-Assembly of Cas9 Ribonucleoprotein Complexes for Cancer Treatment. ACS Nano. 2018; 12(8):7750-7760. DOI: 10.1021/acsnano.8b01670. View

Bialk P, Wang Y, Banas K, Kmiec E . Functional Gene Knockout of Increases Chemosensitivity of Human Lung Cancer A549 Cells and in a Xenograft Mouse Model. Mol Ther Oncolytics. 2018; 11:75-89. PMC: 6251792. DOI: 10.1016/j.omto.2018.10.002. View

10.

Sheng Y, Zhang T, Zhang S, Johnston M, Zheng X, Shan Y . A CRISPR/Cas13a-powered catalytic electrochemical biosensor for successive and highly sensitive RNA diagnostics. Biosens Bioelectron. 2021; 178:113027. DOI: 10.1016/j.bios.2021.113027. View

11.

Gong S, Wang X, Zhou P, Pan W, Li N, Tang B . AND Logic-Gate-Based CRISPR/Cas12a Biosensing Platform for the Sensitive Colorimetric Detection of Dual miRNAs. Anal Chem. 2022; 94(45):15839-15846. DOI: 10.1021/acs.analchem.2c03666. View

12.

Chrysostomou S, Roy R, Prischi F, Thamlikitkul L, Chapman K, Mufti U . Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. Sci Transl Med. 2021; 13(602). PMC: 7611705. DOI: 10.1126/scitranslmed.aba4627. View

13.

Vaishnavi A, Juan J, Jacob M, Stehn C, Gardner E, Scherzer M . Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis. Cancer Res. 2022; 82(22):4261-4273. PMC: 9664136. DOI: 10.1158/0008-5472.CAN-21-3214. View

14.

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S . Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. Nat Med. 2017; 23(11):1362-1368. PMC: 5677540. DOI: 10.1038/nm.4407. View

15.

Togashi Y, Mizuuchi H, Tomida S, Terashima M, Hayashi H, Nishio K . MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer. 2015; 90(3):590-7. DOI: 10.1016/j.lungcan.2015.10.020. View

16.

Xue W, Chen S, Yin H, Tammela T, Papagiannakopoulos T, Joshi N . CRISPR-mediated direct mutation of cancer genes in the mouse liver. Nature. 2014; 514(7522):380-4. PMC: 4199937. DOI: 10.1038/nature13589. View

17.

Sato H, Schoenfeld A, Siau E, Lu Y, Tai H, Suzawa K . MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by Fusions. Clin Cancer Res. 2020; 26(12):2932-2945. PMC: 8034819. DOI: 10.1158/1078-0432.CCR-19-3321. View

18.

Vojnic M, Kubota D, Kurzatkowski C, Offin M, Suzawa K, Benayed R . Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019; 14(5):802-815. PMC: 6486868. DOI: 10.1016/j.jtho.2018.12.038. View

19.

Xu K, Chen G, Li X, Wu X, Chang Z, Xu J . MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep. 2017; 7:41718. PMC: 5296837. DOI: 10.1038/srep41718. View

20.

Rogers Z, McFarland C, Winters I, Naranjo S, Chuang C, Petrov D . A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo. Nat Methods. 2017; 14(7):737-742. PMC: 5495136. DOI: 10.1038/nmeth.4297. View